Skip to main content

Table 4 Multivariable analysis of transplants outcomes

From: Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

Variable

aGvHD II-IV

aGvHD III-IV

cGvHD

Ext. cGvHD

Relapse

NRM

LFS

OS

GRFS

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

Donor type

 MSD

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 MUD

1.39

(0.9–2.15)

0.14

1.22

(0.56–2.64)

0.61

0.96

(0.64–1.45)

0.84

0.98

(0.57–1.7)

0.95

0.79

(0.54–1.16)

0.22

1.38

(0.74–2.61)

0.32

0.93

(0.68–1.29)

0.67

0.91

(0.63–1.3)

0.59

1.01

(0.76–1.33)

0.97

 Haplo

1.60

(1.08–2.37)

0.02

1.76

(0.92–3.37)

0.09

1.21

(0.84–1.75)

0.3

0.87

(0.53–1.42)

0.57

0.67

(0.48–0.93)

0.02

2.60

(1.5–4.49)

< 0.001

1.07

(0.82–1.4)

0.6

1.17

(0.86–1.6)

0.31

1.03

(0.81–1.3)

0.8

Patient’s age per 10 years1

1.05

(0.96–1.17)

0.29

1.00

(0.85–1.18)

0.97

1.03

(0.93–1.14)

0.57

0.95

(0.83–1.09)

0.48

0.97

(0.88–1.06)

0.49

1.35

(1.19–1.54)

< 0.001

1.09

(1.02–1.18)

0.02

1.21

(1.11–1.32)

< 0.001

1.04

(0.97–1.11)

0.26

Karnofsky performance status

 Poor (< 90)

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Good (≥ 90)

0.92

(0.68–1.24)

0.57

0.76

(0.47–1.23)

0.27

0.79

(0.59–1.07)

0.13

0.84

(0.55–1.3)

0.44

0.88

(0.66–1.19)

0.42

0.74

(0.53–1.04)

0.08

0.8

(0.65–0.99)

0.04

0.83

(0.66–1.06)

0.13

0.8

(0.66–0.97)

0.03

Patient´s CMV serostatus

 Negative

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Positive

0.97

(0.72–1.31)

0.86

1.21

(0.71–2.05)

0.49

0.86

(0.65–1.14)

0.28

0.62

(0.42–0.92)

0.02

1.24

(0.92–1.68)

0.16

1.35

(0.91–1.99)

0.13

1.27

(1–1.6)

0.04

1.24

(0.96–1.6)

0.1

1.02

(0.83–1.24)

0.87

Cytogenetic risk category

 Poor

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Standard or intermediate

0.9

(0.66–1.22)

0.48

1.01

(0.59–1.7)

0.98

1.08

(0.79–1.48)

0.63

0.78

(0.5–1.21)

0.26

0.58

(0.43–0.78)

<0.001

1.01

(0.69–1.48)

0.96

0.73

(0.59–0.92)

0.007

0.7

(0.54–0.9)

0.005

0.78

(0.63–0.96)

0.02

 Not available

0.77

(0.53–1.12)

0.17

0.73

(0.39–1.36)

0.32

0.92

(0.64–1.34)

0.66

0.65

(0.39–1.1)

0.11

0.69

(0.49–0.97)

0.03

1

(0.65–1.54)

1

0.79

(0.61–1.02)

0.07

0.81

(0.61–1.07)

0.14

0.81

(0.64–1.03)

0.08

Type of AML

 De novo

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Secondary

0.86

(0.61–1.22)

0.4

1.03

(0.59–1.79)

0.92

1

(0.72–1.37)

0.98

0.83

(0.49–1.4)

0.48

1.20

(0.87–1.64)

0.27

1.08

(0.76–1.55)

0.67

1.18

(0.93–1.49)

0.17

1.20

(0.93–1.54)

0.16

1.11

(0.89–1.38)

0.36

Time from diagnosis to SCT1,2

0.93

(0.83–1.05)

0.24

0.85

(0.68–1.06)

0.16

0.86

(0.75–0.98)

0.03

0.9

(0.75–1.09)

0.29

0.93

(0.82–1.06)

0.29

1.02

(0.89–1.16)

0.79

0.98

(0.89–1.07)

0.6

1

(0.9–1.1)

0.93

0.96

(0.89–1.04)

0.37

Conditioning intensity

 RIC

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 MAC

1.01

(0.76–1.35)

0.93

1.12

(0.7–1.8)

0.64

1.04

(0.77–1.41)

0.81

0.75

(0.5–1.13)

0.17

0.58

(0.43–0.77)

<0.001

0.95

(0.68–1.32)

0.74

0.71

(0.58–0.88)

0.001

0.76

(0.60–0.96)

0.02

0.79

(0.66–0.95)

0.01

Stem cell source

 Bone marrow

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Peripheral blood

1.93

(1.39–2.67)

< 0.001

1.86

(1.1–3.15)

0.02

1.72

(1.24–2.39)

0.001

1.86

(1.15–3.01)

0.01

0.74

(0.55–0.99)

0.04

1.07

(0.76–1.51)

0.69

0.9

(0.73–1.11)

0.31

0.96

(0.75–1.22)

0.73

1.13

(0.93–1.38)

0.2

Donor-recipient gender

 Other combinations

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Female donor to male recipient

0.87

(0.63–1.18)

0.37

1.05

(0.63–1.75)

0.85

1.19

(0.9–1.58)

0.23

1.71

(1.14–2.57)

0.009

0.87

(0.64–1.2)

0.4

1.11

(0.79–1.56)

0.54

0.99

(0.79–1.24)

0.94

1.00

(0.79–1.29)

0.97

1.08

(0.88–1.32)

0.48

Center effect

 

0.04

 

0.27

 

0.01

 

0.28

 

0.22

 

0.06

 

0.25

 

0.13

 

0.28

  1. 1Continuous variable
  2. 2By 2 months increase
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us